F/m Emerald Life Sciences Innovation ETF(LFSC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 9 days
PROFIT SINCE LAST BUY
-10.96% ▼
LAST CLOSE
$41.58
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LFSC

11/20/2026: LFSC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

The F/m Emerald Life Sciences Innovation ETF (LFSC) provides actively managed exposure to innovative U.S. life sciences companies spanning biotechnology, pharmaceuticals, and medical devices. Its main strengths lie in experienced active management and specialized stock selection designed to capture high-growth clinical breakthroughs. It serves primarily as a satellite growth allocation for capturing sector alpha rather than a core portfolio holding. Key risks include high volatility, clinical trial vulnerability, and portfolio concentration. It best suits aggressive growth investors who should monitor regulatory milestones and sector liquidity.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe fund targets cutting-edge life sciences companies positioned for rapid capital appreciation.
Momentum investorStrong fit while signal remains positiveStrong recent price momentum in biotech innovations appeals to trend-following participants.
Value investorWeak fitMany underlying holdings prioritize clinical pipeline development over immediate earnings or free cash flow.
Dividend/Income investorWeak fitThe fund focuses purely on capital growth and does not distribute meaningful dividend yields.
Low-risk investorWeak fitHigh exposure to clinical-stage biotech creates substantial volatility unsuited for conservative profiles.

Investor Profile

Ideal Investor Profile

Growth-oriented investors seeking targeted exposure to pioneering life sciences companies through active management.

Suitability

Best suited for long-term investors willing to tolerate high sector volatility in exchange for potential alpha.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighClinical trial results and regulatory decisions can trigger sharp price swings in underlying biotech stocks.
Market riskMedium / highBroader risk-off sentiment in equities can disproportionately impact speculative healthcare innovators.
ConcentrationHighA significant percentage of assets is clustered within a relatively small number of top holdings.
Tracking/expenseMediumActive management entails a higher expense ratio than passive index alternatives.
LiquidityMedium / highLower average daily volume can lead to wider execution spreads during turbulent market sessions.
Business/sector qualityMediumMany target companies are pre-revenue entities reliant on successful drug commercialization.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

LFSC exhibits high historical volatility characteristic of clinical-stage biotech and specialized healthcare equities.

Market Risk

Subject to regulatory approvals, clinical trial outcomes, and shifting sentiment toward high-growth, non-earnings-yielding equities.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
SectorHealthcare and Life Sciences EquitiesProvides focused exposure to innovative biotechnology, pharmaceutical, and medical device companies.
Single stockTop Life Sciences Holdings (e.g., Cogent Biosciences, LivaNova, Mirum Pharmaceuticals)Represents high-conviction active bets on clinical-stage or commercial-stage medical breakthroughs.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type ETF
Historic Profit 68.93%
Avg. Invested days 91
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.